Cardiovascular Systems Inc - Quarter Report: 2019 December (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________
FORM 10-Q
_____________________________________________________
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2019
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________
Commission File No. 000-52082
____________________________________________________
CARDIOVASCULAR SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
____________________________________________________
| Delaware | 41-1698056 | |||||||
| (State or other jurisdiction of | (IRS Employer | |||||||
| incorporation or organization) | Identification No.) | |||||||
1225 Old Highway 8 Northwest
St. Paul, Minnesota 55112-6416
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (651) 259-1600
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
| Common Stock, One-tenth of One Cent ($0.001) Par Value Per Share | CSII | The Nasdaq Stock Market LLC | ||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | x | Accelerated filer | ☐ | |||||||||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||||||||||||||||
| Emerging growth company | ☐ | |||||||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x
The number of shares outstanding of the registrant’s common stock as of January 31, 2020 was: Common Stock, $0.001 par value per share, 35,247,743 shares.
Cardiovascular Systems, Inc.
Table of Contents
| PAGE | |||||
PART I. — FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Cardiovascular Systems, Inc.
Consolidated Balance Sheets
(Dollars in thousands, except per share and share amounts)
(Unaudited)
| December 31, 2019 | June 30, 2019 | ||||||||||
| ASSETS | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | 65,467 | $ | 74,237 | |||||||
| Marketable securities | 43,954 | 48,435 | |||||||||
| Accounts receivable, net | 35,833 | 36,015 | |||||||||
| Inventories | 21,472 | 18,058 | |||||||||
| Prepaid expenses and other current assets | 2,961 | 3,330 | |||||||||
| Total current assets | 169,687 | 180,075 | |||||||||
| Property and equipment, net | 27,320 | 27,324 | |||||||||
| Intangible assets, net | 20,571 | 5,105 | |||||||||
| Other assets | 6,614 | 6,073 | |||||||||
| Total assets | $ | 224,192 | $ | 218,577 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities | |||||||||||
| Accounts payable | $ | 16,560 | $ | 11,194 | |||||||
| Accrued expenses | 35,074 | 29,387 | |||||||||
| Deferred revenue | 1,656 | 1,764 | |||||||||
| Total current liabilities | 53,290 | 42,345 | |||||||||
| Long-term liabilities | |||||||||||
| Financing obligation | 20,903 | 20,972 | |||||||||
| Deferred revenue | 5,740 | 6,541 | |||||||||
| Other liabilities | 954 | 775 | |||||||||
| Total liabilities | 80,887 | 70,633 | |||||||||
| Commitments and contingencies (see Note 10) | |||||||||||
Common stock, $0.001 par value; authorized 100,000,000 common shares; issued and outstanding 35,251,833 at December 31, 2019 and 34,934,569 at June 30, 2019, respectively | 34 | 34 | |||||||||
| Additional paid in capital | 487,780 | 477,368 | |||||||||
| Accumulated other comprehensive income | 93 | 78 | |||||||||
| Accumulated deficit | (344,602) | (329,536) | |||||||||
| Total stockholders’ equity | 143,305 | 147,944 | |||||||||
| Total liabilities and stockholders’ equity | $ | 224,192 | $ | 218,577 | |||||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
2
Cardiovascular Systems, Inc.
Consolidated Statements of Operations
(Dollars in thousands, except per share and share amounts)
(Unaudited)
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||||
| 2019 | 2018 | 2019 | 2018 | ||||||||||||||||||||
| Net revenues | $ | 68,334 | $ | 60,206 | $ | 132,824 | $ | 116,472 | |||||||||||||||
| Cost of goods sold | 13,718 | 11,477 | 26,390 | 22,052 | |||||||||||||||||||
| Gross profit | 54,616 | 48,729 | 106,434 | 94,420 | |||||||||||||||||||
| Expenses: | |||||||||||||||||||||||
| Selling, general and administrative | 46,867 | 41,107 | 93,619 | 82,349 | |||||||||||||||||||
| Research and development | 10,786 | 7,183 | 21,551 | 14,547 | |||||||||||||||||||
| Amortization of intangible assets | 337 | 55 | 571 | 108 | |||||||||||||||||||
| Total expenses | 57,990 | 48,345 | 115,741 | 97,004 | |||||||||||||||||||
| (Loss) income from operations | (3,374) | 384 | (9,307) | (2,584) | |||||||||||||||||||
| Other (income) expense, net: | |||||||||||||||||||||||
| Interest expense | 500 | 422 | 972 | 846 | |||||||||||||||||||
| Interest income and other, net | (517) | (563) | (1,180) | (1,100) | |||||||||||||||||||
| Total other (income) expense, net | (17) | (141) | (208) | (254) | |||||||||||||||||||
| (Loss) income before income taxes | (3,357) | 525 | (9,099) | (2,330) | |||||||||||||||||||
| Provision for income taxes | 44 | 33 | 82 | 66 | |||||||||||||||||||
| Net (loss) income | $ | (3,401) | $ | 492 | $ | (9,181) | $ | (2,396) | |||||||||||||||
| Basic earnings per share | $ | (0.10) | $ | 0.01 | $ | (0.27) | $ | (0.07) | |||||||||||||||
| Diluted earnings per share | $ | (0.10) | $ | 0.01 | $ | (0.27) | $ | (0.07) | |||||||||||||||
| Basic weighted average shares outstanding | 34,069,412 | 33,507,843 | 33,969,818 | 33,466,454 | |||||||||||||||||||
| Diluted weighted average shares outstanding | 34,069,412 | 34,120,639 | 33,969,818 | 33,466,454 | |||||||||||||||||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
3
Cardiovascular Systems, Inc.
Consolidated Statements of Comprehensive Income
(Dollars in thousands)
(Unaudited)
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||||
| 2019 | 2018 | 2019 | 2018 | ||||||||||||||||||||
| Net (loss) income | $ | (3,401) | $ | 492 | $ | (9,181) | $ | (2,396) | |||||||||||||||
| Other comprehensive income: | |||||||||||||||||||||||
| Unrealized (loss) gain on available-for-sale debt securities | (9) | — | 15 | — | |||||||||||||||||||
| Comprehensive (loss) income | $ | (3,410) | $ | 492 | $ | (9,166) | $ | (2,396) | |||||||||||||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
4
Cardiovascular Systems, Inc.
Consolidated Statements of Changes in Stockholders’ Equity
(Dollars in thousands, except per share amounts)
(Unaudited)
| Common Stock | Additional Paid In Capital | Accumulated Other Comprehensive Income | Accumulated Deficit | Total | |||||||||||||||||||||||||
| Balances at June 30, 2019 | $ | 34 | $ | 477,368 | $ | 78 | $ | (329,536) | $ | 147,944 | |||||||||||||||||||
| Stock-based compensation related to restricted stock awards, net | — | 3,804 | — | — | 3,804 | ||||||||||||||||||||||||
| Shares withheld for payroll taxes | — | — | — | (5,506) | (5,506) | ||||||||||||||||||||||||
| Employee stock purchase plan activity | — | 242 | — | — | 242 | ||||||||||||||||||||||||
| Unrealized gain on available-for-sale debt securities | — | — | 24 | — | 24 | ||||||||||||||||||||||||
| Stock issued for acquisitions | — | 1,346 | — | — | 1,346 | ||||||||||||||||||||||||
| Net loss | — | — | — | (5,780) | (5,780) | ||||||||||||||||||||||||
| Balances at September 30, 2019 | 34 | 482,760 | 102 | (340,822) | 142,074 | ||||||||||||||||||||||||
| Stock-based compensation related to restricted stock awards, net | — | 3,091 | — | — | 3,091 | ||||||||||||||||||||||||
| Shares withheld for payroll taxes | — | — | — | (379) | (379) | ||||||||||||||||||||||||
| Employee stock purchase plan activity | — | 1,929 | — | — | 1,929 | ||||||||||||||||||||||||
| Unrealized loss on available-for-sale debt securities | — | — | (9) | — | (9) | ||||||||||||||||||||||||
| Net loss | — | — | — | (3,401) | (3,401) | ||||||||||||||||||||||||
| Balances at December 31, 2019 | $ | 34 | $ | 487,780 | $ | 93 | $ | (344,602) | $ | 143,305 | |||||||||||||||||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
5
Cardiovascular Systems, Inc.
Consolidated Statements of Changes in Stockholders’ Equity
(Dollars in thousands, except per share amounts)
(Unaudited)
| Common Stock | Additional Paid In Capital | Accumulated Other Comprehensive Income | Accumulated Deficit | Total | |||||||||||||||||||||||||
| Balances at June 30, 2018 | $ | 33 | $ | 461,927 | $ | 101 | $ | (327,591) | $ | 134,470 | |||||||||||||||||||
| Impact from adoption of ASU 2016-01 (See Note 7) | — | — | (101) | 101 | — | ||||||||||||||||||||||||
| Stock-based compensation related to restricted stock awards, net | — | 3,132 | — | — | 3,132 | ||||||||||||||||||||||||
| Shares withheld for payroll taxes | — | — | — | (1,058) | (1,058) | ||||||||||||||||||||||||
| Employee stock purchase plan activity | — | 252 | — | — | 252 | ||||||||||||||||||||||||
| Exercise of stock options at $8.75 per share | — | 71 | — | — | 71 | ||||||||||||||||||||||||
| Net loss | — | — | — | (2,888) | (2,888) | ||||||||||||||||||||||||
| Balances at September 30, 2018 | 33 | 465,382 | — | (331,436) | 133,979 | ||||||||||||||||||||||||
| Stock-based compensation related to restricted stock awards, net | 1 | 2,471 | — | — | 2,472 | ||||||||||||||||||||||||
| Shares withheld for payroll taxes | — | — | — | (319) | (319) | ||||||||||||||||||||||||
| Employee stock purchase plan activity | — | 1,849 | — | — | 1,849 | ||||||||||||||||||||||||
| Exercise of stock options at $8.75 per share | — | 125 | — | — | 125 | ||||||||||||||||||||||||
| Net income | — | — | — | 492 | 492 | ||||||||||||||||||||||||
| Balances at December 31, 2018 | $ | 34 | $ | 469,827 | $ | — | $ | (331,263) | $ | 138,598 | |||||||||||||||||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
6
Cardiovascular Systems, Inc.
Consolidated Statements of Cash Flows
(Dollars in thousands)
(Unaudited)
| Six Months Ended | |||||||||||
| December 31, | |||||||||||
| 2019 | 2018 | ||||||||||
| Cash flows from operating activities | |||||||||||
| Net loss | $ | (9,181) | $ | (2,396) | |||||||
| Adjustments to reconcile net loss to net cash from operating activities | |||||||||||
| Depreciation of property and equipment | 1,493 | 1,577 | |||||||||
| Amortization of intangible assets | 571 | 108 | |||||||||
| Write-off of patent costs | 771 | 300 | |||||||||
| Provision for doubtful accounts | 450 | 100 | |||||||||
| Stock-based compensation | 7,196 | 5,926 | |||||||||
| Accretion of discount on marketable securities | (142) | — | |||||||||
| Changes in assets and liabilities | |||||||||||
| Accounts receivable | (268) | 1,219 | |||||||||
| Inventories | (3,414) | (3,074) | |||||||||
| Prepaid expenses and other assets | 886 | 1,125 | |||||||||
| Accounts payable | 5,409 | 1,479 | |||||||||
| Accrued expenses and other liabilities | (4,642) | (1,868) | |||||||||
| Deferred revenue | (909) | (970) | |||||||||
| Net cash (used in) provided by operating activities | (1,780) | 3,526 | |||||||||
| Cash flows from investing activities | |||||||||||
| Purchases of property and equipment | (1,080) | (994) | |||||||||
| Acquisitions | (5,741) | — | |||||||||
| Purchases of marketable securities | (4,844) | — | |||||||||
| Sales of marketable securities | 85 | 97 | |||||||||
| Maturities of marketable securities | 9,400 | — | |||||||||
| Costs incurred in connection with patents | (573) | (475) | |||||||||
| Net cash used in investing activities | (2,753) | (1,372) | |||||||||
| Cash flows from financing activities | |||||||||||
| Proceeds from employee stock purchase plan | 1,687 | 1,551 | |||||||||
| Payments of employee taxes related to vested restricted stock | (5,885) | (1,377) | |||||||||
| Exercise of stock options | — | 196 | |||||||||
| Principal payments made on financing obligation | (39) | (12) | |||||||||
| Net cash (used in) provided by financing activities | (4,237) | 358 | |||||||||
| Net change in cash and cash equivalents | (8,770) | 2,512 | |||||||||
| Cash and cash equivalents | |||||||||||
| Beginning of period | 74,237 | 116,260 | |||||||||
| End of period | $ | 65,467 | $ | 118,772 | |||||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
7
CARDIOVASCULAR SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(For the Six Months Ended December 31, 2019 and 2018)
(Dollars in thousands, except per share and share amounts)
(Unaudited)
1. Basis of Presentation
Cardiovascular Systems, Inc. (the “Company”), based in St. Paul, Minnesota, is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The Company’s Orbital Atherectomy Systems (“OAS”) treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.
The Company prepared the unaudited interim consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. The year-end consolidated balance sheet was derived from the Company’s audited consolidated financial statements, but does not include all disclosures as required by GAAP. These interim consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary for a fair statement of the Company’s consolidated financial position, the results of its operations, its changes in stockholders’ equity, and its cash flows for the interim periods. These interim consolidated financial statements should be read in conjunction with the consolidated annual financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended June 30, 2019. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.
The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
2. Selected Consolidated Financial Statement Information
Accounts Receivable, Net
Accounts receivable consists of the following:
| December 31, | June 30, | ||||||||||
| 2019 | 2019 | ||||||||||
| Accounts receivable | $ | 36,837 | $ | 36,628 | |||||||
| Less: Allowance for doubtful accounts | (1,004) | (613) | |||||||||
| Accounts receivable, net | $ | 35,833 | $ | 36,015 | |||||||
Inventories
Inventories consist of the following:
| December 31, | June 30, | ||||||||||
| 2019 | 2019 | ||||||||||
| Raw materials | $ | 7,713 | $ | 5,547 | |||||||
| Work in process | 2,039 | 1,415 | |||||||||
| Finished goods | 11,720 | 11,096 | |||||||||
| Inventories | $ | 21,472 | $ | 18,058 | |||||||
8
Property and Equipment, Net
Property and equipment consists of the following:
| December 31, | June 30, | ||||||||||
| 2019 | 2019 | ||||||||||
| Land | $ | 572 | $ | 572 | |||||||
| Building | 22,420 | 22,420 | |||||||||
| Equipment | 18,022 | 17,517 | |||||||||
| Furniture | 2,981 | 2,975 | |||||||||
| Leasehold improvements | 563 | 540 | |||||||||
| Construction in progress | 2,283 | 1,328 | |||||||||
| 46,841 | 45,352 | ||||||||||
| Less: Accumulated depreciation | (19,521) | (18,028) | |||||||||
| Property and equipment, net | $ | 27,320 | $ | 27,324 | |||||||
Accrued Expenses
Accrued expenses consist of the following:
| December 31, | June 30, | ||||||||||
| 2019 | 2019 | ||||||||||
| Acquisition consideration | $ | 9,743 | $ | — | |||||||
| Commissions | 6,920 | 6,829 | |||||||||
| Salaries and bonus | 6,087 | 11,105 | |||||||||
| Accrued vacation | 4,870 | 4,230 | |||||||||
| Accrued excise, sales and other taxes | 2,954 | 3,349 | |||||||||
| Clinical studies | 2,460 | 2,092 | |||||||||
| Other accrued expenses | 2,040 | 1,782 | |||||||||
| Accrued expenses | $ | 35,074 | $ | 29,387 | |||||||
3. Revenue
The following table disaggregates the Company’s net revenues by product category and geography for the following periods:
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||||
| Product Category | 2019 | 2018 | 2019 | 2018 | |||||||||||||||||||
| Peripheral | $ | 47,580 | $ | 44,236 | $ | 93,109 | $ | 85,468 | |||||||||||||||
| Coronary | 20,754 | 15,970 | 39,715 | 31,004 | |||||||||||||||||||
| Total net revenues | $ | 68,334 | $ | 60,206 | $ | 132,824 | $ | 116,472 | |||||||||||||||
| Geography | |||||||||||||||||||||||
| United States | $ | 65,960 | $ | 58,596 | $ | 127,489 | $ | 113,520 | |||||||||||||||
| International | 2,374 | 1,610 | 5,335 | 2,952 | |||||||||||||||||||
| Total net revenues | $ | 68,334 | $ | 60,206 | $ | 132,824 | $ | 116,472 | |||||||||||||||
Revenue of $909 was recognized in the six months ended December 31, 2019 that was deferred as of June 30, 2019. As of December 31, 2019 and June 30, 2019, the Company had a liability of $1,910 and $1,958, respectively, related to estimates of variable consideration which are recorded within accounts payable on the consolidated balance sheet.
9
4. Acquisition
On August 5, 2019, the Company acquired the WIRION Embolic Protection System and related assets from Gardia Medical Ltd. ("Gardia"), a wholly owned Israeli subsidiary of Allium Medical Solutions Ltd., for a total purchase price of $16,687. The device, which received CE Mark in June 2015 and FDA clearance in March 2018, is a distal embolic protection filter used to capture debris that can be associated with all types of peripheral vascular intervention procedures. The Company acquired the device to expand its portfolio of products for physicians that treat complex peripheral arterial disease.
Upon closing, the Company made an initial $5,600 cash payment net of transaction expenses, and issued Gardia 31,493 shares of common stock of the Company valued at $1,346. Following the successful completion of the manufacturing transfer of the WIRION system to the Company, the Company has agreed to pay Gardia an additional $10,000, half of which may be paid by the Company through an additional issuance of shares of common stock. The Company has accounted for this transaction as an asset acquisition resulting in developed technology of $15,624, and a trade name of $760, both recognized as a component of intangible assets, net within the Company's consolidated balance sheet. The remainder of the purchase price was recognized in property and equipment.
The purchase also includes a performance milestone payment to Gardia equal to $3,000 for each $10,000 in net revenues recognized by the Company from sales of the WIRION system for applications above-the-knee in excess of $30,000 during the 36 month period beginning on the earlier of the first commercial sale of the system by the Company or six months following successful manufacturing transfer. If payment of the performance milestone becomes probable, these additional costs will added to the carrying value of the acquired assets.
5. Intangible Assets
The Company’s finite-lived intangible assets are stated at cost less accumulated amortization and include developed technology and trade name assets acquired in the asset acquisition discussed in Note 4, as well as costs incurred to obtain patents. Developed technology and trade name assets are amortized over 15 years. Patent costs are amortized beginning at the time of patent approval over a useful life not exceeding 20 years.
The components of intangible assets, net are as follows:
| December 31, 2019 | June 30, 2019 | ||||||||||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net Book Value | Gross Carrying Amount | Accumulated Amortization | Net Book Value | ||||||||||||||||||
| Developed technology | $ | 15,624 | $ | (434) | $ | 15,190 | $ | — | $ | — | $ | — | |||||||||||
| Patents | 5,705 | (1,063) | 4,642 | 6,093 | (988) | 5,105 | |||||||||||||||||
| Trade name | 760 | (21) | 739 | — | — | — | |||||||||||||||||
| Total intangible assets, net | $ | 22,089 | $ | (1,518) | $ | 20,571 | $ | 6,093 | $ | (988) | $ | 5,105 | |||||||||||
Amortization expense expected for the next five years and thereafter is as follows:
| Remainder of fiscal 2020 | $ | 671 | |||
| Fiscal 2021 | 1,343 | ||||
| Fiscal 2022 | 1,341 | ||||
| Fiscal 2023 | 1,335 | ||||
| Fiscal 2024 | 1,331 | ||||
| Thereafter | 14,550 | ||||
| $ | 20,571 | ||||
6. Debt
Revolving Credit Facility
In March 2017, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). The Loan Agreement provides for a senior, secured revolving credit facility (the “Revolver”) of $40,000 (the “Maximum Dollar Amount”).
10
Advances under the Revolver may be made from time to time up to the Maximum Dollar Amount, subject to certain borrowing limitations. The Revolver has a maturity date of March 31, 2020 and bears interest at a floating per annum rate equal to the Wall Street Journal prime rate, less 0.25%. Interest on borrowings is due monthly and the principal balance is due at maturity. Borrowings up to $10,000 are available on a non-formula basis. Borrowings above $10,000 are based on (i) 85% of eligible domestic accounts receivable, and (ii) the lesser of 50% of eligible inventory or $5,000, subject to adjustment as defined in the Loan Agreement. Upon the Revolver’s maturity, any outstanding principal balance, unpaid accrued interest, and all other obligations under the Revolver will be due and payable. The Company will incur a fee equal to 1% of the Maximum Dollar Amount upon termination of the Loan Agreement or the Revolver for any reason prior to the maturity date, unless refinanced with SVB.
The Company’s obligations under the Loan Agreement are secured by certain of the Company’s assets, including, among other things, accounts receivable, deposit accounts, inventory, equipment, general intangibles and records pertaining to the foregoing. The collateral does not include the Company’s intellectual property, but the Company has agreed not to encumber its intellectual property without the consent of SVB. The Loan Agreement contains customary covenants limiting the Company’s ability to, among other things, incur debt or liens, make certain investments and loans, enter into transactions with affiliates, undergo certain fundamental changes, dispose of assets, or change the nature of its business. In addition, the Loan Agreement contains financial covenants requiring the Company to maintain, at all times when any amounts are outstanding under the Revolver, either (i) minimum unrestricted cash at SVB and unused availability on the Revolver of at least $10,000 or (ii) minimum trailing three-month Adjusted EBITDA of $1,000. If the Company does not comply with the various covenants under the Loan Agreement, the interest rate on outstanding amounts will increase by 5% and SVB may, subject to various customary cure rights, decline to provide additional advances under the Revolver, require the immediate payment of all amounts outstanding under the Revolver, and foreclose on all collateral.
Under the Loan Agreement, the Company paid SVB a non-refundable commitment fee of $80, which will be amortized to interest expense over the term of the Loan Agreement. The Company is required to pay a fee equal to 0.35% per annum on the unused portion of the Revolver, payable quarterly in arrears. The Company is not obligated to draw any funds under the Revolver and has not done so under the Revolver since entering into the Loan Agreement. No amounts are outstanding as of December 31, 2019.
Financing Obligation
In March 2017, in connection with the sale of the Company’s headquarters facility in St. Paul, Minnesota (the “Facility”), the Company entered into a Lease Agreement to lease the Facility. The Lease Agreement has an initial term of 15 years, with four consecutive renewal options of 5 years each at the Company’s option, with a base annual rent in the first year of $1,638 and annual escalations of 3% thereafter. Rent during subsequent renewal terms will be at the then fair market rental rate. As the lease terms resulted in a capital lease classification, the Company accounted for the sale and leaseback of the Facility as a financing transaction where the assets remain on the Company’s balance sheet and a financing obligation was recorded for $20,944. As lease payments are made, they will be allocated between interest expense and a reduction of the financing obligation, resulting in a value of the financing obligation that is equivalent to the net book value of the assets at the end of the lease term. The effective interest rate is 7.89%. At the end of the lease (including any renewal option terms), the Company will remove the assets and financing obligation from its balance sheet.
Payments under the initial term of the Lease Agreement as of December 31, 2019 are as follows:
| Remainder of fiscal 2020 | $ | 882 | |||
| Fiscal 2021 | 1,803 | ||||
| Fiscal 2022 | 1,857 | ||||
| Fiscal 2023 | 1,913 | ||||
| Fiscal 2024 | 1,970 | ||||
| Thereafter | 17,405 | ||||
| $ | 25,830 | ||||
11
7. Marketable Securities & Fair Value Measurements
The Company’s marketable securities are classified on the consolidated balance sheet as follows:
| December 31, | June 30, | ||||||||||
| 2019 | 2019 | ||||||||||
| Short-term available-for-sale debt securities | $ | 33,803 | $ | 38,193 | |||||||
| Long-term available-for-sale debt securities | 9,812 | 9,832 | |||||||||
| Available-for-sale debt securities | 43,615 | 48,025 | |||||||||
| Mutual funds | 339 | 410 | |||||||||
| Total marketable securities | $ | 43,954 | $ | 48,435 | |||||||
Available-for-sale debt securities are invested in the following financial instruments:
As of December 31, 2019 | |||||||||||||||||||||||
| Amortized Cost | Unrealized Gains | Unrealized Losses | Fair Value | ||||||||||||||||||||
| Commercial paper | $ | 4,992 | $ | — | $ | — | $ | 4,992 | |||||||||||||||
| Corporate debt | 28,912 | 84 | — | 28,996 | |||||||||||||||||||
| Asset backed securities | 9,618 | 9 | — | 9,627 | |||||||||||||||||||
| Total available-for-sale debt securities | $ | 43,522 | $ | 93 | $ | — | $ | 43,615 | |||||||||||||||
As of June 30, 2019 | |||||||||||||||||||||||
| Amortized Cost | Unrealized Gains | Unrealized Losses | Fair Value | ||||||||||||||||||||
| Commercial paper | $ | 14,277 | $ | — | $ | — | $ | 14,277 | |||||||||||||||
| Corporate debt | 26,466 | 64 | — | 26,530 | |||||||||||||||||||
| Asset backed securities | 7,204 | 14 | — | 7,218 | |||||||||||||||||||
| Total available-for-sale debt securities | $ | 47,947 | $ | 78 | $ | — | $ | 48,025 | |||||||||||||||
The following table provides information by level for the Company’s marketable securities that were measured at fair value on a recurring basis:
Fair Value Measurements as of December 31, 2019 Using Inputs Considered as | |||||||||||||||||||||||
| Fair Value | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||
| Commercial paper | $ | 4,992 | $ | — | $ | 4,992 | $ | — | |||||||||||||||
| Corporate debt | 28,996 | — | 28,996 | — | |||||||||||||||||||
| Asset backed securities | 9,627 | — | 9,627 | — | |||||||||||||||||||
| Mutual funds | 339 | 105 | 234 | — | |||||||||||||||||||
| Total marketable securities | $ | 43,954 | $ | 105 | $ | 43,849 | $ | — | |||||||||||||||
12
Fair Value Measurements as of June 30, 2019 Using Inputs Considered as | |||||||||||||||||||||||
| Fair Value | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||
| Commercial paper | $ | 14,277 | $ | — | $ | 14,277 | $ | — | |||||||||||||||
| Corporate debt | 26,530 | — | 26,530 | — | |||||||||||||||||||
| Asset backed securities | 7,218 | — | 7,218 | — | |||||||||||||||||||
| Mutual funds | 410 | 121 | 289 | — | |||||||||||||||||||
| Total marketable securities | $ | 48,435 | $ | 121 | $ | 48,314 | $ | — | |||||||||||||||
The Company’s marketable securities classified within Level 1 are valued using real-time quotes for transactions in active exchange markets. Marketable securities within Level 2 are valued using readily available pricing sources. There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the six months ended December 31, 2019. Any transfers between levels would be recognized on the date of the event or when a change in circumstances causes a transfer.
Effective July 1, 2018 the Company adopted the provisions of ASU 2016-01. Unrealized gains and losses of marketable securities in equity investments, denoted as mutual funds, previously recognized in other comprehensive income, will now be recognized in net income as a component of other income.
Non-Marketable Equity Investment
The Company holds an equity investment that does not have a readily determined fair value. The Company has elected to measure this investment at cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Impairment is reviewed each reporting period by performing a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. As of December 31, 2019 and June 30, 2019, the carrying value of the investment was $5,593. During the six months ended December 31, 2019, no impairment indicators were noted. The investment is recorded within other long term assets on the consolidated balance sheet.
8. Stock-Based Compensation
On November 15, 2017, the Company’s stockholders approved the 2017 Equity Incentive Plan (the “2017 Plan”) for the purpose of granting equity awards to employees, directors and consultants. The 2017 Plan replaced the 2014 Equity Incentive Plan (the “2014 Plan”), and no further equity awards may be granted under the 2014 Plan (the 2017 Plan and the 2014 Plan are collectively referred to as the “Plans”).
Equity awards classified as restricted stock and performance-based restricted stock are treated as issued shares when granted; however, these shares are not included in the computation of basic weighted average shares outstanding. When shares vest, unless the holder elects to pay the payroll tax liability in cash or through a sale of shares, the Company withholds the appropriate amount of shares to settle the payroll tax liability, on behalf of the individual receiving the shares, as an adjustment to accumulated deficit.
Restricted Stock
The value of each restricted stock award is equal to the fair market value of the Company’s common stock at the date of grant. Vesting of time-based restricted stock awards ranges from one year to three years. The estimated fair value of restricted stock awards, including the effect of estimated forfeitures, is recognized on a straight-line basis over the restricted stock’s vesting period.
13
Restricted stock award activity for the six months ended December 31, 2019 is as follows:
| Number of Shares | Weighted Average Fair Value | ||||||||||
| Outstanding at June 30, 2019 | 474,945 | $ | 31.36 | ||||||||
| Granted | 185,517 | $ | 46.64 | ||||||||
| Forfeited | (12,489) | $ | 34.44 | ||||||||
| Vested | (182,504) | $ | 30.03 | ||||||||
| Outstanding at December 31, 2019 | 465,469 | $ | 36.86 | ||||||||
Performance-Based Restricted Stock
The Company also grants performance-based restricted stock awards to certain executives and other management. In August 2019, the Company granted an aggregate maximum of 207,891 shares that vest based on the Company’s total shareholder return relative to total shareholder return of the Company’s peer group (a market condition), as measured by the closing prices of the stock of the Company and the peer group members for the 90 trading days preceding July 1, 2019 compared to the closing prices of the stock of the Company and the peer group members for the 90 trading days preceding July 1, 2022. Vesting of these awards will be determined on the date that the Company’s Annual Report on Form 10-K for the fiscal year ending June 30, 2022 is filed.
To calculate the estimated fair value of these restricted stock awards with market conditions, the Company uses a Monte Carlo simulation, which uses the expected average stock prices to estimate the expected number of shares that will vest. The Monte Carlo simulation resulted in an aggregate fair value of approximately $6,330, which the Company will recognize as expense using the straight-line method over the period that the awards are expected to vest. Stock-based compensation expense related to an award with a market condition will be recognized regardless of whether the market condition is satisfied, provided that the requisite service has been provided.
Performance-based restricted stock awards granted in fiscal 2018 and 2019 that are outstanding vest based on the Company’s total shareholder return relative to total shareholder return of the Company’s peer group (a market condition), as measured by the closing prices of the stock of the Company and the peer group members for the 90 trading days preceding July 1, 2017 and July 1, 2018, respectively, compared to the closing prices of the stock of the Company and the peer group members for the 90 trading days preceding July 1, 2020 and July 1, 2021, respectively.
Performance-based restricted stock award activity for the six months ended December 31, 2019 is as follows:
| Number of Shares | Weighted Average Fair Value | ||||||||||
| Outstanding at June 30, 2019 | 753,872 | $ | 15.20 | ||||||||
| Granted | 207,891 | $ | 30.45 | ||||||||
| Forfeited | (25,256) | $ | 16.10 | ||||||||
| Vested | (275,193) | $ | 11.97 | ||||||||
| Outstanding at December 31, 2019 | 661,314 | $ | 21.69 | ||||||||
9. Leases
Effective July 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) Topic 842 - Leases using the modified retrospective transition approach and electing the package of practical expedients. This resulted in the recognition of right-of-use assets of $441 and total operating lease liabilities of $463. There was no cumulative-effect adjustment recorded to retained earnings upon adoption.
The Company leases its Texas manufacturing facilities under an operating lease agreement. During the six months ended December 31, 2019, the Company exercised its option to extend the term of this lease agreement by one year, so that it now expires in April 2021. The Company also leases office equipment under lease agreements that expire at various dates through April 2024.
14
The Company also leases its Minnesota headquarters facility as discussed in Note 6. This transaction did not qualify for sale leaseback accounting upon adoption of ASC 842 and continues to be accounted for as a financing obligation.
Operating lease right-of-use assets and liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement dates. The Company considers fixed or variable payment terms, prepayments, incentives, and options to extend, terminate or purchase. Renewal, termination or purchase options affect the lease term used for determining lease asset value only if the option is reasonably certain to be exercised. The Company uses its incremental borrowing rate based on information available at the lease commencement date in determining the present value of lease payments unless the lease provides an implicit interest rate.
Operating lease cost is classified within the consolidated statement of operations based on the nature of the leased asset. The Company's operating lease cost was $120 and $241 for the three and six months ended December 31, 2019, respectively. Cash paid for operating lease liabilities approximated operating lease cost for the six months ended December 31, 2019. There was $437 of operating lease right-of-use assets obtained in exchange for new lease liabilities during the six months ended December 31, 2019.
| December 31, | |||||
| 2019 | |||||
| Right-of-use assets | |||||
| Other assets | $ | 658 | |||
| Operating lease liabilities | |||||
| Accrued expenses | $ | 492 | |||
| Other liabilities | 175 | ||||
| Total operating lease liabilities | $ | 667 | |||
Future minimum lease payments under the agreements as of December 31, 2019 are as follows:
| Remainder of fiscal 2020 | $ | 255 | |||
| Fiscal 2021 | 423 | ||||
| Fiscal 2022 | 11 | ||||
| Fiscal 2023 | 3 | ||||
| Fiscal 2024 | 2 | ||||
| Thereafter | — | ||||
| Total lease payments | 694 | ||||
| Less imputed interest | (27) | ||||
| Total operating lease liabilities | $ | 667 | |||
As of December 31, 2019, the weighted average remaining lease term for operating leases was 1.4 years and the weighted average discount rate used to determine operating lease liabilities was 5.25%.
10. Commitment and Contingencies
In the ordinary conduct of business, the Company is subject to various lawsuits and claims covering a wide range of matters including, but not limited to, employment claims and commercial disputes. While the outcome of these matters is uncertain, the Company does not believe there are any significant matters as of December 31, 2019 that are probable or estimable, for which the outcome could have a material adverse impact on its consolidated balance sheets or statements of operations.
15
11. Earnings Per Share
The following table presents a reconciliation of the numerators and denominators used in the basic and diluted earnings per common share computations (in thousands except share and per share amounts):
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||||
| 2019 | 2018 | 2019 | 2018 | ||||||||||||||||||||
| Numerator | |||||||||||||||||||||||
| Net (loss) income | $ | (3,401) | $ | 492 | $ | (9,181) | $ | (2,396) | |||||||||||||||
| Income allocated to participating securities | — | (3) | — | — | |||||||||||||||||||
| Net (loss) income available to common stockholders | $ | (3,401) | $ | 489 | $ | (9,181) | $ | (2,396) | |||||||||||||||
| Denominator | |||||||||||||||||||||||
| Weighted average common shares outstanding – basic | 34,069,412 | 33,507,843 | 33,969,818 | 33,466,454 | |||||||||||||||||||
Effect of dilutive restricted stock units(1) | — | 327,662 | — | — | |||||||||||||||||||
Effect of performance-based restricted stock awards(2) | — | 285,134 | — | — | |||||||||||||||||||
Weighted average common shares outstanding – diluted | 34,069,412 | 34,120,639 | 33,969,818 | 33,466,454 | |||||||||||||||||||
| Earnings per common share – basic | $ | (0.10) | $ | 0.01 | $ | (0.27) | $ | (0.07) | |||||||||||||||
| Earnings per common share – diluted | $ | (0.10) | $ | 0.01 | $ | (0.27) | $ | (0.07) | |||||||||||||||
(1)At December 31, 2019 and 2018, 365,818 and 354,176 additional shares of common stock, respectively, were issuable upon the settlement of outstanding restricted stock units. The effect of the shares that would be issued upon settlement of these restricted stock units has been excluded from the calculation of diluted loss per share for the three and six months ended December 31, 2019, and the six months ended December 31, 2018, because those shares are anti-dilutive.
(2)At December 31, 2019 and 2018, 661,314 and 740,097 performance-based restricted stock awards, respectively, were outstanding. The effect of the potential vesting of these awards has been excluded from the calculation of diluted loss per share for the three and six months ended December 31, 2019, and the six months ended December 31, 2018, because those shares are anti-dilutive.
Unvested time-based restricted stock awards that contain nonforfeitable rights to dividends are participating securities and included in the computation of earnings per share pursuant to the two-class method. Under this method, earnings attributable to the Company are allocated between common stockholders and the participating awards, as if the awards were a second class of stock. During periods of net income, the calculation of earnings per share excludes the income attributable to participating securities in the numerator and the dilutive impact of these securities from the denominator. In the event of a net loss, undistributed earnings are not allocated to participating securities and the denominator excludes the dilutive impact of these securities as they do not share in the losses of the Company. During the three months ended December 31, 2018, undistributed earnings allocated to participating securities were based on 191,331 time-based restricted stock awards. During the three and six months ended December 31, 2019, and the six months ended December 31, 2018 there were no undistributed earnings allocated to participating securities due to the net losses.
16
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing under Item 1 of Part I of this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and expected financial results, includes forward-looking statements that involve risks and uncertainties. You should review the “Risk Factors” discussed in our Annual Report on Form 10-K for the year ended June 30, 2019 and subsequent Quarterly Reports on Form 10-Q, including in Item 1A of Part II of this Quarterly Report on Form 10-Q, for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
OVERVIEW
We are a medical technology company leading the way in the effort to successfully treat patients living with peripheral and coronary artery diseases, including those with arterial calcium, the most difficult arterial disease to treat. We are committed to clinical rigor, constant innovation and a defining drive to set the industry standard to deliver safe and effective medical devices that improve lives of patients facing these difficult disease states.
We have observed some degree of seasonality in our business, as there tends to be a lower number of procedures that use our products during the three months ending September 30. Interventional procedure volume usually grows throughout the course of the fiscal year, with the three months ending June 30 usually representing the highest volume of cases and, therefore, the highest amount of revenue generated by us during the course of the fiscal year.
Peripheral
Our peripheral arterial disease (“PAD”) products are catheter-based platforms capable of treating a broad range of plaque types in leg arteries both above and below the knee, including calcified plaque, and address many of the limitations associated with other existing surgical, catheter and pharmacological treatment alternatives. The micro-invasive devices use small access sheaths that can provide procedural benefits, allow physicians to treat PAD patients in even the small and tortuous vessels located below the knee, and facilitate access through alternative sites in the ankle, foot and wrist, as well as in the groin.
The United States Food and Drug Administration (“FDA”) has granted us 510(k) clearances for our Peripheral OAS as a therapy in patients with PAD, as discussed in Item 1 of Part I of our Annual Report on Form 10-K for the year ended June 30, 2019. We refer to these products in this Quarterly Report on Form 10-Q as the “Peripheral OAS.” In addition to our Peripheral OAS, we also offer support products within the peripheral space. Peripheral sales in the United States during the six months ended December 31, 2019 represented 70% of revenue.
Coronary
Our coronary artery disease (“CAD”) product, the Diamondback 360 Coronary OAS (“Coronary OAS”), is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions. The Coronary OAS design is similar to technology used in our Peripheral OAS, customized specifically for the coronary application. In addition to the Coronary OAS, we also offer support products within the coronary space as we expand treatment to a broader patient population with complex coronary artery disease.
In October 2013, we received premarket approval (“PMA”) from the FDA to market the Coronary OAS as a treatment for severely calcified coronary arteries and we commenced a commercial launch that same month. Coronary sales in the United States during the six months ended December 31, 2019 represented approximately 26% of revenue.
International
Sales of our approved products in Japan are made through our exclusive Japan distributor, Medikit Co., Ltd. ("Medikit"). Sales of our products in the rest of the world, which primarily includes certain countries in Southeast Asia, Europe and the Middle East, are made through our exclusive international distributor, OrbusNeich®. International sales during the six months ended December 31, 2019 represented approximately 4% of revenue.
17
CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES
Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of our consolidated financial statements requires us to make estimates, assumptions and judgments that affect amounts reported in those statements. Our estimates, assumptions and judgments, including those related to revenue recognition, deferred revenue and stock-based compensation, are updated as appropriate at least quarterly. We use authoritative pronouncements, our technical accounting knowledge, cumulative business experience, judgment and other factors in the selection and application of our accounting policies. While we believe that the estimates, assumptions and judgments that we use in preparing our consolidated financial statements are appropriate, these estimates, assumptions and judgments are subject to factors and uncertainties regarding their outcome. Therefore, actual results may materially differ from these estimates.
Some of our significant accounting policies require us to make subjective or complex judgments or estimates. An accounting estimate is considered to be critical if it meets both of the following criteria: (1) the estimate requires assumptions about matters that are highly uncertain at the time the accounting estimate is made, and (2) different estimates that reasonably could have been used, or changes in the estimate that are reasonably likely to occur from period to period, would have a material impact on the presentation of our financial condition, results of operations, or cash flows.
Our critical accounting policies are identified in Item 7 of Part II of our Annual Report on Form 10-K for the fiscal year ended June 30, 2019 under the heading “Critical Accounting Policies and Significant Judgments and Estimates.”
RESULTS OF OPERATIONS
The following table sets forth our results of operations expressed as dollar amounts (in thousands) and the changes between the specified periods expressed as percent increases or decreases:
| Three Months Ended December 31, | Six Months Ended December 31, | ||||||||||||||||||||||||||||||||||
| 2019 | 2018 | Percent Change | 2019 | 2018 | Percent Change | ||||||||||||||||||||||||||||||
| Net revenues | $ | 68,334 | $ | 60,206 | 13.5 | % | $ | 132,824 | $ | 116,472 | 14.0 | % | |||||||||||||||||||||||
| Cost of goods sold | 13,718 | 11,477 | 19.5 | 26,390 | 22,052 | 19.7 | |||||||||||||||||||||||||||||
| Gross profit | 54,616 | 48,729 | 12.1 | 106,434 | 94,420 | 12.7 | |||||||||||||||||||||||||||||
| Expenses: | |||||||||||||||||||||||||||||||||||
| Selling, general and administrative | 46,867 | 41,107 | 14.0 | 93,619 | 82,349 | 13.7 | |||||||||||||||||||||||||||||
| Research and development | 10,786 | 7,183 | 50.2 | 21,551 | 14,547 | 48.1 | |||||||||||||||||||||||||||||
| Amortization of intangible assets | 337 | 55 | 512.7 | 571 | 108 | 428.7 | |||||||||||||||||||||||||||||
| Total expenses | 57,990 | 48,345 | 20.0 | 115,741 | 97,004 | 19.3 | |||||||||||||||||||||||||||||
| (Loss) income from operations | (3,374) | 384 | (978.6) | (9,307) | (2,584) | (260.2) | |||||||||||||||||||||||||||||
| Other (income) expense, net | (17) | (141) | (87.9) | (208) | (254) | (18.1) | |||||||||||||||||||||||||||||
| (Loss) income before income taxes | (3,357) | 525 | (739.4) | (9,099) | (2,330) | (290.5) | |||||||||||||||||||||||||||||
| Provision for income taxes | 44 | 33 | 33.3 | 82 | 66 | 24.2 | |||||||||||||||||||||||||||||
| Net (loss) income | (3,401) | 492 | (791.3) | $ | (9,181) | $ | (2,396) | (283.2) | |||||||||||||||||||||||||||
18
Comparison of Three Months Ended December 31, 2019 with Three Months Ended December 31, 2018
Net revenues. Net revenues increased by $8.1 million, or 13.5%, from $60.2 million for the three months ended December 31, 2018 to $68.3 million for the three months ended December 31, 2019. Peripheral revenues increased $3.3 million, or 7.6%, and coronary revenues increased $4.8 million, or 30.0%. Both peripheral and coronary revenue increases were primarily driven by higher unit volumes as a result of the growth of our customer base and expansion into new international markets, and new product offerings such as balloons, guidewires, and catheters. Revenue growth from unit volume increases was partially offset by lower average selling prices. International revenue was $2.4 million for the three months ended December 31, 2019, compared with international revenue of $1.6 million for the three months ended December 31, 2018, an increase of $800,000. We expect our revenue to increase as we continue to increase the number of physicians using the devices, increase the usage per physician, introduce new and improved products, generate additional clinical data, and expand into new geographies through our distribution agreements with Medikit and OrbusNeich, partially offset by potential decreases in average selling prices.
Cost of Goods Sold. Cost of goods sold increased to $13.7 million for the three months ended December 31, 2019 from $11.5 million for the three months ended December 31, 2018, a 19.5% increase. These amounts represent the cost of materials, labor and overhead for single-use catheters, guide wires, pumps, and other ancillary products. The increase in cost of goods sold was due to greater unit volumes as we added new accounts, expanded internationally and offered additional products. Gross margin decreased to 79.9% for the three months ended December 31, 2019 from 80.9% for the three months ended December 31, 2018, primarily due to increased sales of lower margin products, expansion into lower margin international markets through distributor relationships, and lower average selling prices. This decrease was partially offset by product cost reductions and manufacturing efficiencies. We expect that gross margin in the third quarter of fiscal 2020 will be similar to gross margin in the three months ended December 31, 2019. Quarterly margin fluctuations could occur based on production volumes, timing of new product introductions, sales mix, pricing changes, or other unanticipated circumstances.
Selling, General and Administrative Expenses. Our selling, general and administrative expenses increased by $5.8 million, or 14.0%, from $41.1 million for the three months ended December 31, 2018 to $46.9 million for the three months ended December 31, 2019. The increase was primarily due to increased expenses related to additional clinical specialists within our sales organization, the expansion of our medical affairs initiatives and international expansion. Selling, general and administrative expenses for the three months ended December 31, 2019 and 2018 include $2.7 million and $2.4 million, respectively, for stock-based compensation. We expect our selling, general and administrative expenses for the third quarter of fiscal 2020 to be consistent with amounts incurred for the three months ended December 31, 2019.
Research and Development Expenses. Research and development expenses increased by $3.6 million, or 50.2%, from $7.2 million for the three months ended December 31, 2018 to $10.8 million for the three months ended December 31, 2019. Research and development expenses relate to specific projects to develop new products or expand into new markets, such as the development of new versions of the Peripheral and Coronary OAS, shaft designs and crown designs, and to PAD and CAD clinical trials. The increase was primarily due to increased personnel and project costs for the three months ended December 31, 2019 as we invested in expanding our product portfolio and additional costs associated with the ECLIPSE clinical study. Research and development expenses for the three months ended December 31, 2019 and 2018 include $393,000 and $307,000, respectively, for stock-based compensation. We expect research and development expenses in the third quarter of fiscal 2020 to be consistent with amounts incurred for the three months ended December 31, 2019 based on the timing of our investments in the expansion of our product portfolio and clinical studies. Fluctuations could occur based on the number of projects and studies, the progress of such projects and studies, the rate of study enrollment, and the timing of expenditures.
Comparison of Six Months Ended December 31, 2019 with Six Months Ended December 31, 2018
Net revenues. Net revenues increased by $16.3 million, or 14.0%, from $116.5 million for the six months ended December 31, 2018 to $132.8 million for the six months ended December 31, 2019. Peripheral revenues increased $7.6 million, or 8.9%, and coronary revenues increased $8.7 million, or 28.1%. Both peripheral and coronary revenue increases were primarily driven by higher unit volumes as a result of the growth of our customer base and expansion into new international markets, and new product offerings such as balloons guidewires and catheters, partially offset by lower average selling prices. International revenue was $5.3 million for the six months ended December 31, 2019, compared with $3.0 million for the six months ended December 31, 2018, an increase of $2.3 million.
19
Cost of Goods Sold. Cost of goods sold increased to $26.4 million for the six months ended December 31, 2019 from $22.1 million for the six months ended December 31, 2018, a 19.7% increase. These amounts represent the cost of materials, labor and overhead for single-use catheters, guide wires, pumps, and other ancillary products. The increase in cost of goods sold was due to greater unit volumes as we added new accounts, expanded internationally and offered additional products. Gross margin decreased to 80.1% for the six months ended December 31, 2019 from 81.1% for the six months ended December 31, 2018, primarily due to increased sales of lower margin products, expansion into lower margin international markets through distributor relationships, and lower average selling prices. This decrease was partially offset by product cost reductions and manufacturing efficiencies.
Selling, General and Administrative Expenses. Our selling, general and administrative expenses increased by $11.3 million, or 13.7%, from $82.3 million for the six months ended December 31, 2018 to $93.6 million for the six months ended December 31, 2019. The increase was primarily due to increased expenses related to the expansion of our medical affairs initiatives, additional clinical specialists within our sales organization and international expansion. Selling, general and administrative expenses for the six months ended December 31, 2019 and 2018 include $5.8 million and $5.0 million, respectively, for stock-based compensation.
Research and Development Expenses. Research and development expenses increased by $7.0 million, or 48.1%, from $14.6 million for the six months ended December 31, 2018 to $21.6 million for the six months ended December 31, 2019. Research and development expenses relate to specific projects to develop new products or expand into new markets, such as the development of new versions of the Peripheral and Coronary OAS, shaft designs and crown designs, and to PAD and CAD clinical trials. The increase was primarily due to increased personnel costs as we invested in expanding our product portfolio and additional costs associated with the ECLIPSE clinical study. Research and development expenses for the six months ended December 31, 2019 and 2018 include $1.0 million and $728,000, respectively, for stock-based compensation.
LIQUIDITY AND CAPITAL RESOURCES
We had cash and cash equivalents of $65.5 million and $74.2 million at December 31, 2019 and June 30, 2019, respectively. As of December 31, 2019, we had an accumulated deficit of $344.6 million. We have historically funded our operating losses primarily from the issuance of common and preferred stock, convertible promissory notes, and debt.
A summary of our cash flow activities is as follows:
| Six Months Ended | |||||||||||
| December 31, | |||||||||||
| 2019 | 2018 | ||||||||||
| Net cash (used in) provided by operating activities | $ | (1,780) | $ | 3,526 | |||||||
| Net cash used in investing activities | (2,753) | (1,372) | |||||||||
| Net cash (used in) provided by financing activities | (4,237) | 358 | |||||||||
| Net change in cash and cash equivalents | $ | (8,770) | $ | 2,512 | |||||||
Changes in Liquidity
Operating Activities
Net cash used in operating activities was $1.8 million for the six months ended December 31, 2019, primarily due to the net loss of $9.2 million, and increased use of cash as we build inventory and diversify our products, as well as for payouts of previously accrued bonuses and commissions. The amount of cash used was partially offset by collections on receivables, increased accounts payable due to timing of activity and payments, and non-cash expenditures for the six months ended December 31, 2019.
Net cash provided by operating activities was $3.5 million for the six months ended December 31, 2018, primarily due to positive cash flow when the net loss of $2.4 million is adjusted for non-cash expenditures such as stock-based compensation, depreciation and amortization. Contributing to positive cash flows from operations was the timing of collections on receivables and of cash payments on payables. These positive cash flows were partially offset by the increased use of cash as we build inventory and diversify our products, as well as for payouts of previously accrued bonuses and commissions.
20
Investing Activities
Net cash used in investing activities was $2.8 million for the six months ended December 31, 2019, primarily due to the cash payment made for the WIRION acquisition, additional purchases of marketable securities, purchases of property and equipment and costs associated with capitalized patent activities. These uses of cash were partially offset by maturities of marketable securities.
Net cash used in investing activities was $1.4 million for the six months ended December 31, 2018, primarily due to purchases of property and equipment and costs associated with capitalized patent activities.
Financing Activities
Net cash used in financing activities was $4.2 million for the six months ended December 31, 2019, primarily due to the payment of payroll taxes on the employee vesting of stock awards, partially offset by proceeds from employee stock purchases.
Net cash provided by financing activities was $358,000 for the six months ended December 31, 2018, primarily due to proceeds from employee stock purchases and the exercise of stock options, partially offset by the payment of payroll taxes on the employee vesting of stock awards.
Our future liquidity and capital requirements will be influenced by numerous factors, including the extent and duration of future operating losses, the level and timing of future sales and expenditures, the results and scope of ongoing research and product development programs, working capital required to support our business operations, the receipt of and time required to obtain regulatory clearances and approvals, our sales and marketing programs, the continuing acceptance of our products in the marketplace, competing technologies, market and regulatory developments, ongoing facility requirements, potential strategic transactions (including the potential acquisition of, or investments in, businesses, technologies and products), international expansion, and the existence, defense and resolution of legal proceedings. As of December 31, 2019, we believe our current cash and cash equivalents will be sufficient to fund working capital requirements, capital expenditures and operations for the foreseeable future, including at least the next twelve months, as well as to fund expenses relating to compliance with our Corporate Integrity Agreement, payments under our lease agreements, payments under development agreements and anticipated costs relating to litigation. We intend to retain any future earnings to support operations and to finance the growth and development of our business. We do not anticipate paying any dividends in the foreseeable future.
Facility Sale and Lease
On December 29, 2016, we entered into a Purchase and Sale Agreement, as subsequently amended (collectively, the “Sale Agreement”), with Krishna Holdings, LLC (“Krishna”), providing for the sale to Krishna of our headquarters facility in St. Paul, Minnesota (the “Facility”) for a cash purchase price of $21.5 million. On March 30, 2017, the sale of the Facility under the Sale Agreement closed. We received proceeds of approximately $20.9 million ($21.5 million less $556,000 of transaction expenses). In connection with the closing of the facility sale, we entered into a Lease Agreement (the “Lease Agreement”) with Krishna Holdings, LLC, Apex Holdings, LLC, Kashi Associates, LLC, Keva Holdings, LLC, S&V Ventures, LLC, Polo Group LLC, SPAV Holdings LLC, Star Associates LLC, and The Global Villa, LLC. The Lease Agreement has an initial term of fifteen years, with four consecutive renewal options of five years each, with a base annual rent in the first year of $1.6 million and annual escalations of 3%. See Note 6 to our Consolidated Financial Statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q for additional discussion.
Revolving Credit Facility
On March 31, 2017, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). The Loan Agreement provides for a senior, secured revolving credit facility (the “Revolver”) of $40.0 million (the “Maximum Dollar Amount”).
Advances under the Revolver may be made from time to time up to the Maximum Dollar Amount, subject to certain borrowing limitations. The Revolver has a maturity date of March 31, 2020 and bears interest at a floating per annum rate equal to the Wall Street Journal prime rate, less 0.25%. Interest on borrowings is due monthly and the principal balance is due at maturity. Borrowings up to $10.0 million are available on a non-formula basis. Borrowings above $10.0 million are based on (i) 85% of eligible domestic accounts receivable, and (ii) the lesser of 50% of eligible inventory or $5.0 million, subject to adjustment as defined in the Loan Agreement. Upon the Revolver’s maturity, any outstanding principal balance, unpaid accrued interest, and all other obligations under the Revolver will be due and payable. We will incur a fee equal to 1% of the Maximum Dollar
21
Amount upon termination of the Loan Agreement or the Revolver for any reason prior to the maturity date, unless refinanced with SVB.
Our obligations under the Loan Agreement are secured by certain of our assets, including, among other things, accounts receivable, deposit accounts, inventory, equipment, general intangibles and records pertaining to the foregoing. The collateral does not include our intellectual property, but we agreed not to encumber our intellectual property without the consent of SVB. The Loan Agreement contains customary covenants limiting our ability to, among other things, incur debt or liens, make certain investments and loans, enter into transactions with affiliates, undergo certain fundamental changes, dispose of assets, or change the nature of our business. In addition, the Loan Agreement contains financial covenants requiring us to maintain, at all times when any amounts are outstanding under the Revolver, either (i) minimum unrestricted cash at SVB and unused availability on the Revolver of at least $10.0 million or (ii) minimum trailing three-month Adjusted EBITDA (as defined in the Loan Agreement) of $1.0 million. If we do not comply with the various covenants under the Loan Agreement, the interest rate on outstanding amounts will increase by 5% and SVB may, subject to various customary cure rights, decline to provide additional advances under the Revolver, require the immediate payment of all amounts outstanding under the Revolver, and foreclose on all collateral.
Under the Loan Agreement, we paid SVB a non-refundable commitment fee of $80,000, which will be amortized to interest expense over the term of the Loan Agreement. We are required to pay a fee equal to 0.35% per annum on the unused portion of the Revolver, payable quarterly in arrears. We are not obligated to draw any funds under the Revolver and have not done so under the Revolver since entering into the Loan Agreement. No amounts are outstanding as of December 31, 2019 and we currently do not have plans to borrow under the Loan Agreement.
NON-GAAP FINANCIAL INFORMATION
To supplement our consolidated financial statements prepared in accordance with GAAP, our management uses a non-GAAP financial measure referred to as “Adjusted EBITDA.” The following table sets forth, for the periods indicated, a reconciliation of Adjusted EBITDA to the most comparable GAAP measure expressed as dollar amounts (in thousands):
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||||
| 2019 | 2018 | 2019 | 2018 | ||||||||||||||||||||
| Net (loss) income | (3,401) | 492 | $ | (9,181) | $ | (2,396) | |||||||||||||||||
| Less: Other (income) expense, net | (17) | (141) | (208) | (254) | |||||||||||||||||||
| Less: Provision for income taxes | 44 | 33 | 82 | 66 | |||||||||||||||||||
| (Loss) income from operations | (3,374) | 384 | (9,307) | (2,584) | |||||||||||||||||||
| Add: Stock-based compensation | 3,290 | 2,770 | 7,196 | 5,926 | |||||||||||||||||||
| Add: Depreciation and amortization | 1,090 | 831 | 2,064 | 1,685 | |||||||||||||||||||
| Adjusted EBITDA | $ | 1,006 | $ | 3,985 | $ | (47) | $ | 5,027 | |||||||||||||||
Adjusted EBITDA decreased for the three and six months ended December 31, 2019 as compared to the three and six months ended December 31, 2018 primarily due to a greater loss from operations.
Use and Economic Substance of Non-GAAP Financial Measures Used and Usefulness of Such Non-GAAP Financial Measures to Investors
We use Adjusted EBITDA as a supplemental measure of performance and believe this measure facilitates operating performance comparisons from period to period and company to company by factoring out potential differences caused by depreciation and amortization expense and non-cash charges such as stock-based compensation. Our management uses Adjusted EBITDA to analyze the underlying trends in our business, assess the performance of our core operations, establish operational goals and forecasts that are used to allocate resources and evaluate our performance period over period and in relation to our competitors’ operating results. Additionally, our management is partially evaluated on the basis of Adjusted EBITDA when determining achievement of their incentive compensation performance targets. Management does not use Adjusted EBITDA as a liquidity measure or in the calculation of our financial covenants under the loan and security agreement with Silicon Valley Bank.
22
We believe that presenting Adjusted EBITDA provides investors greater transparency to the information used by our management for its financial and operational decision-making and allows investors to see our results “through the eyes” of management. We also believe that providing this information better enables our investors to understand our operating performance and evaluate the methodology used by our management to evaluate and measure such performance.
The following is an explanation of each of the items that management excludes from Adjusted EBITDA and the reasons for excluding each of these individual items:
•Stock-based compensation. Our management believes that excluding this item from Adjusted EBITDA is useful to investors to understand the application of stock-based compensation guidance and its impact on our operational performance and ability to make additional investments in our company, and excluding this item allows for greater transparency to certain line items in our financial statements.
•Depreciation and amortization expense. Our management believes that excluding these items from our Adjusted EBITDA is useful to investors to understand our operational performance and ability to make additional investments in our company.
Material Limitations Associated with the Use of Non-GAAP Financial Measures and Manner in Which We Compensate for these Limitations
Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP. Some of the limitations associated with our use of these non-GAAP financial measures are:
•Items such as stock-based compensation do not directly affect our cash flow position; however, such items reflect economic costs to us and are not reflected in our Adjusted EBITDA, and therefore Adjusted EBITDA does not reflect the full economic effect of these items.
•Non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles and therefore other companies may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.
•Our management exercises judgment in determining which types of charges or other items should be excluded from the non-GAAP financial measures we use.
We compensate for these limitations by relying primarily upon our GAAP results and using non-GAAP financial measures only supplementally.
INFLATION
We do not believe that inflation had a material impact on our business and operating results during the periods presented.
OFF-BALANCE SHEET ARRANGEMENTS
Since inception, we have not engaged in any off-balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.
RECENT ACCOUNTING PRONOUNCEMENTS
For a description of recent accounting pronouncements, see Note 1 to the Consolidated Financial Statements included in Item 8 of Part II of our Annual Report on Form 10-K for the year ended June 30, 2019.
PRIVATE SECURITIES LITIGATION REFORM ACT
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Such “forward-looking” information is included in this Quarterly Report on Form 10-Q and in other materials filed or to be filed by us with the SEC (as well as information included in oral statements or other written statements made or to be made by us). Forward-looking statements include all statements based on future expectations. This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties, including, but not limited to, (i) our expectation of continued sales of our products internationally, including the specific products to be sold, the territories in which such products will be sold, and the timing of such sales; (ii) seasonality in our business; (iii) our expectation that our revenue will increase; (iv) our expectation
23
that we will incur selling, general and administrative expenses in the third quarter of fiscal 2020 consistent with the amounts incurred in the three months ended December 31, 2019; (v) our expectation that gross margin in the third quarter of fiscal 2020 will be similar to gross margin in the three months ended December 31, 2019; (vi) our expectation that we will incur research and development expenses in the third quarter of fiscal 2020 consistent with the amounts incurred in the three months ended December 31, 2019; (vii) our belief that our current cash and cash equivalents will be sufficient to fund working capital requirements, capital expenditures and operations for the foreseeable future, as well as to fund certain other anticipated expenses; (viii) our intention to retain any future earnings to support operations and to finance the growth and development of our business; (ix) our dividend expectations; (x) our plan not to borrow under our loan and security agreement; and (xi) the anticipated impact of adoption of recent accounting pronouncements on our financial statements.
In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management’s beliefs and assumptions, which in turn are based on their interpretation of currently available information.
These statements involve known and unknown risks, uncertainties and other factors that may cause our results or our industry’s actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These factors include regulatory developments, clearances and approvals; approval of our products for distribution in foreign countries; approval of products for reimbursement and the level of reimbursement in the United States, Japan and other foreign countries; dependence on market growth; agreements with third parties to sell their products; the ability of OrbusNeich to successfully launch our products outside of the United States and Japan; our ability to maintain third-party supplier relationships and renew existing purchase agreements; our ability to maintain our relationships with Medikit and OrbusNeich; the experience of physicians regarding the effectiveness and reliability of the products we sell; the reluctance of physicians, hospitals and other organizations to accept new products; the potential for unanticipated delays in enrolling medical centers and patients for clinical trials; actual clinical trial and study results; the impact of competitive products and pricing; our ability to comply with the financial covenants in our loan and security agreement and to make payments under and comply with the lease agreement for our corporate headquarters; unanticipated developments affecting our estimates regarding expenses, future revenues and capital requirements; the difficulty of successfully managing operating costs; our ability to manage our sales force strategy; actual research and development efforts and needs, including the timing of product development programs; our ability to obtain and maintain intellectual property protection for product candidates; fluctuations in results and expenses based on new product introductions, sales mix, unanticipated warranty claims, and the timing of project expenditures; our ability to manage costs; our actual financial resources and our ability to obtain additional financing; investigations or litigation threatened or initiated against us; court rulings and future actions by the FDA and other regulatory bodies; international trade developments; the impact of federal corporate tax reform on our business, operations and financial statements; shutdowns of the U.S. federal government; unanticipated developments during the manufacturing transfer process for the WIRION system; and general economic conditions.
These and additional risks and uncertainties are described more fully in our Annual Report on Form 10-K for the year ended June 30, 2019 and subsequent Quarterly Reports on Form 10-Q, including in Item 1A of Part II of this Quarterly Report on Form 10-Q. Copies of filings made with the SEC are available through the SEC’s electronic data gathering analysis and retrieval system (EDGAR) at www.sec.gov.
You should read these risk factors and the other cautionary statements made in this Quarterly Report on Form 10-Q as being applicable to all related forward-looking statements wherever they appear in this Quarterly Report on Form 10-Q. We cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should read this Quarterly Report on Form 10-Q completely. Other than as required by law, we undertake no obligation to update these forward-looking statements, even though our situation may change in the future.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There have been no material changes in our primary risk exposures or management of market risks from those disclosed in our Annual Report on Form 10-K for the year ended June 30, 2019.
24
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our Chief Executive Officer and Chief Financial Officer, referred to collectively herein as the Certifying Officers, are responsible for establishing and maintaining our disclosure controls and procedures. The Certifying Officers have reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of December 31, 2019. Based on that review and evaluation, which included inquiries made to certain other of our employees, the Certifying Officers have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures, as designed and implemented, are effective.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended December 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
25
PART II. — OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this Quarterly Report on Form 10-Q, including the important information in the section entitled “Private Securities Litigation Reform Act,” you should carefully consider the “Risk Factors” in our Annual Report on Form 10-K for the year ended June 30, 2019 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in this Quarterly Report on Form 10-Q and materially adversely affect our business, financial condition and/or future operating results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also might materially adversely affect our business, financial condition and/or operating results.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Company Repurchases of Equity Securities
The following table presents information with respect to purchases made by us of our common stock during the second quarter of fiscal 2020:
| Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased under the Plans or Programs | ||||||||||||||||||||
| October 1 to October 31, 2019 | — | — | N/A | N/A | |||||||||||||||||||
November 1 to November 30, 2019(1) | 8,623 | 43.94 | N/A | N/A | |||||||||||||||||||
| December 1 to December 31, 2019 | — | — | N/A | N/A | |||||||||||||||||||
| 8,623 | $ | 43.94 | |||||||||||||||||||||
(1) Comprised of shares withheld pursuant to the terms of restricted stock awards under our stock-based compensation plans to offset tax withholding obligations that occur upon vesting and release of shares. The value of the shares withheld is the closing price of our common stock on the date the relevant transaction occurs.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
None.
ITEM 5. OTHER INFORMATION
None.
26
ITEM 6. EXHIBITS
| Exhibit No. | Description | |||||||
| 31.1* | ||||||||
| 31.2* | ||||||||
| 32.1** | ||||||||
| 32.2** | ||||||||
| 101* | Financial statements from the Quarterly Report on Form 10-Q of the Company for the quarter ended December 31, 2019, formatted in XBRL: (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Income, (iv) the Consolidated Statements of Changes in Stockholders’ Equity, (v) the Consolidated Statements of Cash Flows, and (vi) the Notes to Financial Statements. | |||||||
| 104* | Cover page interactive data file (formatted in Inline XBRL and contained in Exhibit 101). | |||||||
_______________________
* Filed herewith.
** Furnished herewith.
27
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: February 6, 2020 | CARDIOVASCULAR SYSTEMS, INC. | ||||||||||
| By | /s/ Scott R. Ward | ||||||||||
| Scott R. Ward | |||||||||||
| Chairman, President and Chief Executive Officer | |||||||||||
| (Principal Executive Officer) | |||||||||||
| By | /s/ Jeffrey S. Points | ||||||||||
| Jeffrey S. Points | |||||||||||
| Chief Financial Officer | |||||||||||
| (Principal Financial and Accounting Officer) | |||||||||||
28